Pharmaceuticals are a poor example because the (bulk of the) costs aren’t inherent to the discovery process, rather they are caused by the regulatory process th

Pharmaceuticals are a poor example because the (bulk of the) costs aren’t inherent to the discovery process, rather they are caused by the regulatory process that ensure safety for patients. I don’t see a good reason why that same regulatory process shouldn’t grant a limited monopoly instead of depending on patent protection.